Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236350 | 0.88 | FAAH (0.54) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL7778319 | 0.86 | FAAH (0.61) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL26012635 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL2805775 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL4572566 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL2554949 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL9550539 | 0.82 | FAAH (0.66) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL28571485 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL15602675 | 0.82 | FAAH (0.66) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 | |
| SCHEMBL14113350 | 0.81 | ALDH1A1 (0.42) | ALDH1A1MAPTFAAHSMN1; SMN2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| EP-1474146-B1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | ALDH1A1 1102/4885MAPT 761/4885FAAH 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.